Bone News and Research

RSS

CMAJ publishes new, updated guidelines on vitamin D

New and updated guidelines on recommended vitamin D intake have been published this week in the online issue of the Canadian Medical Association Journal.

14 Jul 2010

LSUHSC Professor awarded $2.1M grant to determine role of PCP

Dr. Jay Kolls, Professor and Chairman of Genetics at the LSU Health Sciences Center New Orleans School of Medicine, has been awarded a $2.1 million grant over five years by the National Heart, Lung, and Blood Institute of the National Institutes of Health to determine the role and identify which T-helper cells fight the opportunistic infection, Pneumocystis carinii pneumonia, which can be a complication of HIV/AIDS.

14 Jul 2010

ChemGenex agrees with FDA on potential regulatory path to progress OMAPRO for CML

ChemGenex Pharmaceuticals Limited announced today it has agreed with the U.S. Food and Drug Administration (FDA) on a potential regulatory path to progress OMAPRO™ (omacetaxine mepesuccinate) for the treatment of patients with Chronic Myeloid Leukemia (CML).

14 Jul 2010

Custom-made bone replacements for facial reconstruction soon

Facial reconstruction patients may soon have the option of custom-made bone replacements optimized for both form and function, thanks to researchers at the University of Illinois and the Ohio State University Medical Center.

13 Jul 2010

Researchers use topological optimization to design facial bone replacements

Scientists are using the engineering technology behind the creation of high-performance aircraft components to design 3-D models for the replacement of delicate and complex facial bones lost to cancer surgery or trauma.

13 Jul 2010

Protalix BioTherapeutics' taliglucerase alfa for Gaucher disease granted French ATU

Protalix BioTherapeutics, Inc. announced today that the French regulatory authority has granted an Autorisation Temporaire d'Utilisation (ATU), or Temporary Authorization for Use, for taliglucerase alfa for the treatment of Gaucher disease. An ATU is the regulatory mechanism used by the French Health Products and Safety Agency to make non-approved drugs available to patients in France when a genuine public health need exists.

13 Jul 2010

Researchers discover single genetic mutation that accounts for disease

By inspecting the sequence of all 3 billion "letters" that make up the genome of a single person affected with a rare, inherited disorder, a Johns Hopkins and Duke University team ferreted out the single genetic mutation that accounts for the disease.

13 Jul 2010

New approach in treating heart attack, cardiomyopathy using stem cells

Presenting at the UK National Stem Cell Network annual science conference today (13 July), Professor Michael Schneider describes a new approach to treating heart attack and cardiomyopathy using stem cells.

13 Jul 2010

Men with prostate cancer lose less bone mineral content as they age: Study

Men with prostate cancer lose significantly less bone mineral content (BMC) as they age than men who are free of the disease, according to research in the July issue of BJUI. The findings are important because loss of BMC can play a key role in the development of fragile bones, fractures and osteoporosis.

13 Jul 2010

Asuragen, Life Technologies announce European launch of BCR/ABL1 Quant Test

Asuragen, Inc. and Life Technologies Corporation announced today that they have achieved CE-marking and commercial launch in Europe of the BCR/ABL1 Quant™ Test, Asuragen's clinically validated and cGMP manufactured test intended to aid clinicians in the monitoring and treatment of individuals afflicted with chronic myeloid leukemia (CML). Asuragen manufacturers the monitoring test, which is exclusively distributed by Life Technologies and runs on the company's Applied Biosystems CE-marked 7500 Fast Dx Real-Time PCR Instrument™.

13 Jul 2010

Biomet fourth-quarter net sales increase 10% to $702.5M

Biomet, Inc. announced today financial results for its fourth quarter and fiscal year ended May 31, 2010.

13 Jul 2010

$Binge-drinking teenagers at risk for future osteoporosis, bone fractures$

Binge-drinking teenagers at risk for future osteoporosis, bone fractures

Binge-drinking teenagers may be putting themselves at risk for future osteoporosis and bone fractures, according to researchers at Loyola University Health System.

13 Jul 2010

Older adults with low levels of vitamin D more likely to experience cognitive decline: Report

Older adults with low levels of vitamin D appear more likely to experience declines in thinking, learning and memory over a six-year period, according to a report in the July 12 issue of Archives of Internal Medicine, one of the JAMA/Archives journals.

13 Jul 2010

BioMimetic announces common stock public offering

BioMimetic Therapeutics, Inc. announced today a public offering of 5,000,000 shares of its common stock. BioMimetic has granted the underwriters an option to purchase up to an additional 15% of shares of common stock to cover over-allotments. BioMimetic expects to use the net proceeds of the offering for development and commercialization of its product pipeline and general corporate purposes.

13 Jul 2010

Novelos reports positive results from NOV-002 Phase 2 neoadjuvant breast cancer trial

Novelos Therapeutics, Inc., a biopharmaceutical company developing therapeutics to treat cancer and hepatitis, today announced positive results in a Phase 2 trial of NOV-002 in combination with neoadjuvant chemotherapy treatment in patients with stage IIB-IIIC HER-2/neu negative invasive breast cancer, conducted by the Braman Family Breast Cancer Institute at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine.

12 Jul 2010

FDA accepts Protalix's taliglucerase alfa NDA, assigns PDUFA action date

Protalix BioTherapeutics, Inc., announced today that the Company's New Drug Application (NDA) for taliglucerase alfa has been accepted for review by the U.S. Food and Drug Administration (FDA). The FDA granted taliglucerase alfa a standard review time of ten months, assigning a Prescription Drug User Fee Act (PDUFA) action date of February 25, 2011.

12 Jul 2010

MDT releases statement questioning AGD's priorities

The dentists who form Millennium Dental Technologies, Inc., and are pioneers of the patented LANAP protocol for the treatment of gum disease and the manufacturer of the PerioLase MVP-7 digital dental laser, today released a statement questioning the Academy of General Dentistry's priorities.

12 Jul 2010

Vanderbilt Medical Center treats first patient in Galil Medical's new TRACE renal registry

Galil Medical, a global leader in minimally invasive cryotherapy cancer treatments, today announced that Vanderbilt University Medical Center in Nashville, Tenn., has treated the first patient to be included in its new patient registry.

12 Jul 2010

Hip and knee specialist indicates five primary reasons why knee implant fails

While most knee replacements will function well for years, patients should be aware of the signs of failure—including increased pain or decreased function—that may require a corrective procedure known as revision total knee replacement, if necessary.

12 Jul 2010

Mesoblast schedules formal meeting with FDA to discuss proposed Phase 3 clinical trial program

Australian regenerative medicine company, Mesoblast Limited, today announced that based on positive results from its bone marrow transplant clinical trial conducted at the University of Texas MD Anderson Cancer Center, a formal meeting has been scheduled with the United States Food and Drug Administration to discuss a proposed Phase 3 clinical trial program.

12 Jul 2010